NCT01303029已完成2 期
A Phase IIb Randomized Study to Evaluate the Efficacy of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2011年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
The purpose of the study is to evaluate the efficacy of the combination of gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in patients with metastatic pancreatic cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to understand and willingness to sign a written informed consent
- •Able, in the investigator's opinion, to fulfill the procedures and explorations of the study
- •Age ≥ 18 years old
- •Life expectancy ≥ 12 weeks
- •Patients with metastatic adenocarcinoma of the pancreas, following 7th edition of TNM classification
- •Histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas
- •Measurable disease following RECIST criteria version 1.1
- •No previous systemic treatment for metastatic pancreatic cancer Adjuvant chemotherapy al least 6 months before enrollment is allowed. Patients having neoadjuvant chemotherapy must have completed the treatment at least 4 weeks before trial entry. Toxicities associated to previous treatment must be resolved before enrollment. Progression disease (metastatic disease) must be confirmed after adjuvant treatment
- •Adequate bone marrow function as determined by:
- •Hemoglobin: ≥ 9 g/dL. (patients with hemoglobin < 9 g/dL could be transfused before their inclusion on the study)
- •Platelets: ≥ 100 x 109/L
- •Absolute Neutrophil account (ANC) ≥ 1,5 x 109/L
- •Adequate liver function, as determined by:
- •Serum bilirubin ≤ 1,5 x LSN
- •AST, ALT ≤ 2,5 x LSN in patients without liver metastasis. In patients with liver metastasis ≤ 5 x LSN
- •Alkaline phosphatase ≤ 2,5 x LSN or ≤ 5 x LSN in patients with liver metastasis. In patients with bone metastasis ≤ 10 x LSN
- •Adequate renal function, as determined by:
- •Creatinine clearance using the Cockcroft-Gault formula ≥ 50.0 ml/min
- •Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to randomization. Postmenopausal women are defined as those who have been amenorrheic for at least 12 months. Also, both men and women enrolled in this study must use adequate birth control (eg., abstinence, intrauterine device, oral contraceptive or double barrier method or be surgically sterile), starting at the signing of the informed consent and up to at least 6 months after completion of treatment or the last dose, whichever occurs first
- •Patients must not have undergone a major surgical procedure within 4 weeks prior to study treatment. The surgical wound should be completely healed
排除标准
- •Local pancreatic cancer (stage IA-IIB) or locally advance cancer (stage III), following the TNM 7th edition classification. Patients with metastatic disease that relapse after the initial diagnosis of local or advance disease could be included in this study
- •Pancreatic endocrine tumor and ampulloma
- •Evidence of carcinomatosis meningitis or brain metastasis. In case of clinical suspicious of brain metastasis is mandatory to perform a brain TAC/MR 4 weeks prior de inclusion.
- •Primary tumors developed 5 years previous to the inclusion, except in situ cervix carcinoma or skin basocellular cancer properly treated
- •Cardiovascular disease clinically significant (active):
- •Non-controlled arterial hypertension (Systolic pressure > 150 mg Hg and/or diastolic pressure > 100 mm Hg on repeated pressure measurements)
- •Cerebrovascular accident/ictus (≤ 6 weeks prior to inclusion)
- •Myocardial infarction (≤ 6 months prior to inclusion)
- •Unstable angina
- •Congestive cardiac insufficiency (grade II or superior following to New York Heart Association (NYHA)
- •Severe cardiac arrythmia requiring treatment
- •Significant ophthalmologic anomalies
- •Deficit in Dihydropyrimidine-Dehydrogenase (DPD)
- •Unable to take oral drug. Previous surgical process that affect the absorption or make the needed to have intravenous feeding or parenteral nutrition with lipids
- •Pregnancy women or in lactation period
- •Antineoplastic treatment (chemotherapy, hormonal treatment, radiotherapy, surgery, biological therapy or tumor embolization) 4 weeks prior the inclusion
- •Previous treatment with capecitabine or EGFR inhibitor
- •Metabolic disease or any other disease which, in the investigator's opinion, might interfere with the treatment in study
- •Known hypersensibility to any study drug (gemcitabine, erlotinib, capecitabine) or to 5-fluorouracile and fluoropyrimidines
- •Current infection grade ≥ 2 (CTCAE)
- •Known human immunodeficiency virus infection, or chronic infection with hepatitis B or C virus, or severe uncontrolled intercurrent infection or other severe uncontrolled concomitant diseases
- •Medical, psychological, psychiatric or sociological conditions that would interfere to the patient participation in the study or in the assessment of the results
- •Current or 30 days previous to study treatment with other investigational drug or participation in other trial
研究组 & 干预措施
Control
Active Comparator
Gemcitabine+erlotinib
干预措施: Gemcitabine+erlotinib (Drug)
Experimental
Experimental
Gemcitabine+erlotinib+capecitabine
干预措施: Gemcitabine+erlotinib+capecitabine (Drug)
结局指标
主要结局
Progression free survival
时间窗: 4 years
次要结局
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability(4 years)
- Duration of response(4 years)
- Overall survival(4 years)
- Response rate (RR)(4 years)
- Percentage of rash in patients treated with erlotinib and progression free survival and overall survival and treatment relationship(4 years)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic CancerPancreatic CancerNCT00564720Hellenic Oncology Research Group140
已完成
2 期
Study of Gemcitabine and Vinorelbine in Soft Tissue SarcomasSarcoma, Soft TissueNCT00134641Dana-Farber Cancer Institute40
暂停
2 期
A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic CancerPancreatic CancerNCT00536770Novacea132
已完成
2 期
Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic CancerMetastatic Pancreatic CancerNCT00922896Gyeongsang National University Hospital22
已完成
2 期
Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerNCT00154739National Taiwan University Hospital86